RevitalVision today announced its U.S. market entry with a portfolio of digital training therapies clinically proven to improve vision in conditions such as adult amblyopia, keratoconus, nystagmus, and early presbyopia.
Its groundbreaking programs have been available in Europe since 2022.
The innovative technology offers eye care professionals (ECPs) an effective tool to improve patients' vision beyond available eye treatments by utilizing a proprietary algorithm to visually stimulate the brain’s visual cortex.
The technology has been clinically validated to enhance vision outcomes with long lasting results in a wide range of eye diseases and vision impairments, with significant impact on vision and quality of life.
The prescribed, home-based, vision training, software operates directly from a standard web browser on any personal computer without the need for any special hardware.
RevitalVision is the only FDA-cleared product for amblyopia beyond childhood ages 9 and older.
Central to the company’s U.S. strategy is close collaboration with ECPs to improve patient experiences and outcomes. The company has partnered with Launchpad Vision to introduce the technology across seven key U.S. regions, including nearly 20 pilot practices.
“RevitalVision therapy has given me the game-changing opportunity to help patients that I otherwise couldn’t with current technologies,” said Jordan Dau, OD, of Dau Family Eyecare in Jacksonville, Florida. “After reviewing the outcomes from its extensive clinical studies, my opinion of RevitalVision technology evolved from it being a unique idea to a compelling treatment option that scratches the surface of how many patients it can help. The programs have been a great addition to our practice and make me excited for the ways it can benefit both patients and the eye care profession.”
As part of RevitalVision’s U.S. infrastructure build-out, Charles Morris has been appointed as general manager, North America.
Most recently he held roles as global brand director for CooperVision’s specialty eyecare portfolio and director of marketing for Paragon Vision Sciences.
“We believe there’s no better time to bring our comprehensive, non-invasive approach to vision enhancement to the U.S. market than right now. On average, patients experience a 2.5 line improvement on the visual acuity chart and a 100% increase in contrast sensitivity,” said Morris. “Initial success from our pilot practices has been extremely encouraging, and we are enthusiastic about sharing our proven science and technology with optometrists and their teams nationwide this year.”
RevitalVision will be exhibiting at booth L8 (adjacent to the main stage) at Vision Expo East from February 20 – February 22, 2025, in Orlando. Attendees will have the chance to experience live demonstrations, meet with company experts, discuss clinical trials, and learn more about the technology behind the therapy.
For more information about RevitalVision, please visit www.revitalvision.com.